Patented Medicine Prices Review Board

• Canada’s drug pricing conflict sparked by health minister letter, emails show

  Emails suggest some on the regulator's board believed the crisis that followed the minister's letter threatened the very survival of the agency.

  Politics

  Jun 8, 2023
  
• Canada’s health minister denies interfering in agency’s efforts to lower drug costs

  Health Minister Jean-Yves Duclos says he has not exercised any undue political pressure on the independent federal agency that regulates the price of patented drugs.

  Health

  Apr 27, 2023
  
• Advertisement
• Director of Canada’s drug price regulator resigns same week as colleague steps down

  The executive director of Canada's drug pricing regulator is stepping down days after another member resigned because of concerns the federal government was undermining their work.

  Health

  Feb 24, 2023
• Advertisement
• Member of Canada’s drug pricing regulator quits over ‘lack of support’ for medicine cost reforms

  A member of the Patented Medicine Prices Review Board has resigned over what he calls a 'lack of support' from the federal government and failure to implement reforms.

  Canada

  Feb 23, 2023
• New drug price rule could save Canada billions, parliamentary budget officer reports

  The new drug pricing regulation, which is set to lower spending on patented drugs, will come into effect in July 1 after being pushed back four times during the pandemic.

  Health

  Jun 14, 2022
• Liberals put 6-month pause on efforts to lower cost of patented medicines

  Health Canada first announced in 2019 that the Patented Medicine Prices Review Board (PMPRB) would change how it sets a price cap on medicines in Canada.

  Canada

  Dec 23, 2021
• Canada battling pharmaceutical companies over new pricing rules, patients caught in the middle

  Canada wants to prevent medicines from being "excessively priced," making pharma companies question implementation of life-saving drugs here.

  Canada

  Dec 9, 2020
• Canadian prescription drug prices come under scrutiny of U.S. trade representative

  In its annual report on foreign perils to American rights holders, the office of the U.S. Trade Representative is raising concerns about Canada's plan to recalibrate how it calculates the price of prescription drugs.

  May 1, 2020